Angiogenesis Inhibitors: all 4,430 studies that test it
Page 1 of 45. Open to participants first (542), then studies with results posted, then the rest; newest registration first within each.
- First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal MesotheliomaNot yet recruitingNCT07893340Phase 2
- VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) StudyNot yet recruitingNCT07891182Phase 2
- PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver CancerRecruitingNCT07884877Phase 2
- SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular CarcinomaNot yet recruitingNCT07882056Phase 2
- Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.Not yet recruitingNCT07864480Phase 4
- A Prospective, Single-center, Phase II Study of Neoadjuvant Serplulimab Plus XELOX and Bevacizumab in Locally Advanced Rectal CancerNot yet recruitingNCT07854964Not applicable
- A Study to Compare GNR-139 and Eylea® in Patients With nAMDRecruitingNCT07844148Phase 3
- Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingNCT07843303Phase 2
- Early Prophylactic Versus Late Salvage Recombinant Human Endostatin in Managing Radiosurgery-Induced Brain Injury for NSCLC Brain MetastasesNot yet recruitingNCT07841106Phase 2
- Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSLRecruitingNCT07839247Phase 2
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid TumorsNot yet recruitingNCT07833735Phase 1/2
- Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)Not yet recruitingNCT07831122Phase 1
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07830485Phase 2
- Bevacizumab in the Treatment of HHTRecruitingNCT07828015Phase 2
- Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple MyelomaRecruitingNCT07825064Phase 2
- Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingNCT07821606Phase 3
- Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal CancerNot yet recruitingNCT07819604Phase 2
- SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLCNot yet recruitingNCT07818304Phase 2
- mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal CancerNot yet recruitingNCT07817888Phase 2
- Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell TherapyNot yet recruitingNCT07814001Phase 2
- ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced HepatocellularNot yet recruitingNCT07813572Phase 3
- A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular EdemaRecruitingNCT07812090Phase 2
- Platinum-Free Regimen in Nasopharyngeal CarcinomaNot yet recruitingNCT07794488Phase 2
- An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid TumorsNot yet recruitingNCT07774611Phase 1/2
- Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular CarcinomaNot yet recruitingNCT07774247Phase 2
- Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal AdenocarcinomaNot yet recruitingNCT07763171Phase 3
- Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular CarcinomaNot yet recruitingNCT07761286Phase 1/2
- Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line ResponseNot yet recruitingNCT07760610Phase 4
- Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.Not yet recruitingNCT07757412Phase 2
- Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)Not yet recruitingNCT07756840Phase 2
- South Asian Patients With Diabetic Macular Oedema Treated With Faricimab Assessing the Efficacy, Durability, and Safety (SEAFAR Study)Not yet recruitingNCT07753616Phase 4
- A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerNot yet recruitingNCT07750041Phase 1/2
- Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCLRecruitingNCT07749365Phase 2
- Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.Not yet recruitingNCT07748689Phase 2
- The Efficacy of CAPCT in Patients With PTCLNot yet recruitingNCT07746245Phase 2
- FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRCNot yet recruitingNCT07729605Phase 3
- Intra-Arterial Bevacizumab as an Adjunct to Middle Meningeal Artery Embolization for Chronic Subdural HematomaNot yet recruitingNCT07729098Phase 1
- Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD PatientsNot yet recruitingNCT07728981Early Phase 1
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT07728188Phase 3
- Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 TrialRecruitingNCT07722754Phase 2
- IBI363 Combined With Bevacizumab for Advanced Colorectal CancerRecruitingNCT07722494Phase 3
- A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular LymphomaNot yet recruitingNCT07719855Phase 3
- Efficacy and Safety of Lenalidomide in Patients With IgG4-Related DiseaseNot yet recruitingNCT07719543Phase 3
- Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)Not yet recruitingNCT07714317Phase 1/2
- A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd RegimenNot yet recruitingNCT07709884Phase 4
- A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis SyndromeRecruitingNCT07695298Phase 4
- A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular CarcinomaNot yet recruitingNCT07691762Phase 3
- Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System DiseaseNot yet recruitingNCT07681297Phase 1/2
- Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled TrialNot yet recruitingNCT07681167Phase 2
- A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal CancerRecruitingNCT07676162Phase 3
- Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta ThalassemiaRecruitingNCT07673302Not applicable
- Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid TumorsRecruitingNCT07671534Phase 2
- Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term ProgressionRecruitingNCT07670026Phase 2
- Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian CancerNot yet recruitingNCT07663513Phase 2
- A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung CancerNot yet recruitingNCT07661173Phase 2
- A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.RecruitingNCT07653685Phase 1/2
- CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell LeukemiaRecruitingNCT07652905Phase 2
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelRecruitingNCT07649525Phase 3
- Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian CancerNot yet recruitingNCT07647653Phase 2
- Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal NeovascularizationRecruitingNCT07642960Not applicable
- Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCCRecruitingNCT07639138Phase 2
- Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.RecruitingNCT07638852Phase 2
- Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian CancerNot yet recruitingNCT07637851Phase 1/2
- Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)RecruitingNCT07627347Not applicable
- Sac-TMT Combined With Bevacizumab in TNBC With Brain MetastasesRecruitingNCT07623577Phase 2
- A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract CancerRecruitingNCT07619235Phase 4
- Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With SchizophreniaNot yet recruitingNCT07615075Phase 4
- A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular DegenerationRecruitingNCT07614776Phase 3
- Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple MyelomaNot yet recruitingNCT07600151Phase 1/2
- AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCLNot yet recruitingNCT07594899Phase 2
- Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaNot yet recruitingNCT07594548Phase 1
- A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and LenalidomideNot yet recruitingNCT07585747Phase 2
- Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF AgentsRecruitingNCT07567833Phase 4
- A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular CarcinomaRecruitingNCT07557251Phase 1
- A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)RecruitingNCT07549412Phase 3
- SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RCRecruitingNCT07549399Phase 3
- Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 TrialNot yet recruitingNCT07543783Phase 2
- SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal CancerNot yet recruitingNCT07535632Phase 2
- Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or LymphomaRecruitingNCT07532525Phase 1
- Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerRecruitingNCT07527858Phase 2
- Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell LymphomaRecruitingNCT07523737Phase 2
- Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar RanibizumabRecruitingNCT07520045Not applicable
- Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine CarcinomaRecruitingNCT07518602Phase 2
- Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07515625Phase 2
- Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal CancerRecruitingNCT07500298Phase 1
- JSKN033 Combination Therapy in Subjects With Advanced Cervical CancerNot yet recruitingNCT07497074Phase 2
- Identifying Effective and Cost-Conscious Maintenance Daratumumab DosingRecruitingNCT07485647Phase 2
- Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain MetastasesRecruitingNCT07481786Phase 3
- A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT07478302Phase 1
- A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaRecruitingNCT07477457Phase 2
- Efficacy and Safety of Thalidomide for Pediatric PFAPA SyndromeNot yet recruitingNCT07476625Not applicable
- SYS6090 Combination Therapy in Advanced Lung CancerNot yet recruitingNCT07472647Phase 1/2
- PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal CancerRecruitingNCT07472140Phase 2/3
- Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal VasculopathyRecruitingNCT07461441Phase 3
- Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT07460362Phase 2
- Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZLRecruitingNCT07448324Phase 2
- Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II StudyRecruitingNCT07446452Phase 2
- A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)RecruitingNCT07425522Phase 1
- Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung DiseaseNot yet recruitingNCT07420439Phase 2
- Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular LymphomaRecruitingNCT07418190Phase 2